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GENE THERAPY
Sustained high-level polyclonal hematopoietic marking and transgene expression
4 years after autologous transplantation of rhesus macaques with SIV lentiviral
vector–transduced CD34 cells
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Children’s Research Hospital, Memphis, TN; 3Genome Technology Branch, National Human Genome Research Institute, NIH, Bethesda, MD; 4Mouse Cancer
Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick, MD; and 5Department of Immunology, St Jude Children’s Research
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We previously reported that lentiviral vec-
tors derived from the simian immunodefi-
ciency virus (SIV) were efficient at
transducing rhesus hematopoietic re-
populating cells. To evaluate the persis-
tence of vector-containing and -expressing
cells long term, and the safety implications
of SIV lentiviral vector–mediated gene
transfer, we followed 3 rhesus macaques
for more than 4 years after transplanta-
tion with transduced CD34 cells. All 3 ani-
mals demonstrated significant vector
marking and expression of the GFP trans-
gene in T cells, B cells, and granulocytes,
with mean GFP levels of 6.7% (range,
3.3%-13.0%), 7.4% (4.2%-13.4%), and 5.6%
(3.1%-10.5%), respectively. There was no
vector silencing in hematopoietic cells
over time. Vector insertion site analysis
of granulocytes demonstrated sustained
highly polyclonal reconstitution, with no
evidence for progression to oligoclonal-
ity. A significant number of clones were
found to contribute at both 1-year and
3- or 4-year time points. No vector integra-
tions were detected in the MDS1/EVI1
region, in contrast to our previous find-
ings with a -retroviral vector. These data
show that lentiviral vectors can mediate
stable and efficient long-term expression
in the progeny of transduced hematopoi-
etic stem cells, with an integration profile
that may be safer than that of standard
Moloney murine leukemia virus (MLV)–
derived retroviral vectors. (Blood. 2009;
113:5434-5443)
Introduction
Hematopoietic stem cells (HSCs) are important targets for gene
therapy because of their dual capacities for both self-renewal and
differentiation, thereby having the potential for correction of gene
defects in various blood cell lineages for the lifetime of an person.
Successful gene therapy directed at HSCs depends on achieving
sufficient levels of gene transfer to long-term engrafting cells with
persistent expression of the transgene in vector-containing progeny
cells of the desired lineage. Two decades of intense vector
development, preclinical testing, and early clinical trials have made
HSC gene therapy a reality, with evidence of clinical benefit in
several congenital immunodeficiency disorders.1-4 To date, all
published HSC gene therapy clinical trials have used integrating
modified replication-defective murine -retroviral vectors that
underwent an extensive process of optimization and testing using
in vitro, rodent, and large-animal models.5
Successful genomic integration of -retroviral vectors re-
quires cycling of target cells to allow the relatively unstable
preintegration complex to enter the nucleus and access chroma-
tin.6 This requirement for active cell division is likely a major
obstacle to achieving consistent high-level gene transfer into
quiescent HSCs with -retroviral vectors. This constraint is a
significant hurdle for wider applications of HSC gene therapy,
particularly to diseases such as hemoglobinopathies where,
unlike the immunodeficiency disorders, corrected early progeni-
tor cells do not have a marked survival or proliferative
advantage and high levels of initial HSC gene transfer would be
required for clinical benefit.7
In addition to the difficulties associated with achieving
efficient transduction of HSCs, -retroviral vectors have now
been found to present serious safety issues.8 A total of 5 patients
enrolled in 2 clinical gene therapy trials using these vectors to
transduce HSCs in patients with X-linked severe combined
immunodeficiency (X-SCID) have developed clonal, vector-
associated T-cell leukemias, 3 or more years after transplanta-
tion.9-12 In 4 of the cases, vector insertions near the proto-
oncogene LMO2 resulted in aberrant activation and contributed
to the leukemogenic process.10 -Retroviral vectors have also
been linked to insertional activation of proto-oncogenes with
resultant myeloid tumors in small- and large-animal models.13,14
There is accumulating evidence that several characteristics of
-retroviral vectors may be associated with significant genotox-
icity, including the presence of strong enhancer elements in the
proviral long terminal repeats (LTRs) able to activate adjacent
genes, and nonrandom integration preferences favoring integra-
tion in or near actively expressed genes (often proto-oncogenes
in primitive cycling hematopoietic cells) and surrounding
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transcription start sites.15-20 These limitations of -retroviral
vectors have prompted investigators to identify and evaluate
alternative vector systems that might reduce the risks of
insertional mutagenesis while potentially increasing the effi-
ciency of gene transfer.
Compared with -retroviral vectors, lentiviral vectors derived
from the human immunodeficiency virus (HIV) or simian immuno-
deficiency virus (SIV) may allow higher efficiency HSC gene
transfer. Lentiviral vectors can transduce noncycling or slowly
cycling target cells due to a more stable preintegration complex that
is able to cross the nuclear membrane.21,22 In addition, they
facilitate the use of complex expression cassettes that allow
precisely regulated transgene expression.23 However, development
of lentiviral vectors for clinical applications has lagged behind
standard -retroviral vectors, and only one clinical trial, targeting
lymphocytes, has been completed.24 Several trials targeting HSCs
with lentiviral vectors in patients with adrenoleukodystrophy or
-thalassemia have recently been initiated.
We previously reported that SIV lentiviral vectors were efficient
at transducing rhesus CD34 cells, resulting in high-level in vivo
marking with transduced progeny cells up to 6 months after
transplantation.25 A comparison of vector integration sites in these
animals at this early time point compared with animals that
received a transplant of -retroviral transduced CD34 cells
revealed distinct patterns for each. SIV vector integrants were
markedly concentrated within entire transcription units and particu-
larly gene-dense regions of the genome, whereas -retroviral
vector integrants were more often in proximity to transcriptional
start sites (TSSs).16
It took more than 3 years after transplantation for patients
and macaques that received a transplant of -retroviral vector–
transduced HSCs to develop overt hematologic malignancies,
and serial transplantation in mouse models to result in clonal
dominance or leukemia.10-13,26,27 Therefore, long-term follow-up
in relevant models is critical to fully assess the potential risks
associated with vector insertion into HSCs. Nonhuman primates
are a particularly relevant animal model for assessing long-term
safety and efficacy.28 In the current study, we report detailed
follow-up of 3 rhesus macaques that received a transplant of SIV
vector–transduced autologous CD34 cells more than 4 years
ago. Our data demonstrate stable levels of vector-containing
cells and transgene expression in all hematopoietic lineages, and
a polyclonal pattern of vector insertion sites without the marked
overrepresentation of recurrent integrations in or near worri-
some proto-oncogenes such as LMO2 or MDS1/EVI1.
Methods
Transduction of CD34 mobilized PB cells and autologous
transplantation of rhesus macaques
Rhesus macaques (Macacca mulatta) were housed and handled in accor-
dance with guidelines set by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources, National
Research Council, and the animal protocol was approved by the Animal
Care and Use Committee of the National Heart, Lung, and Blood Institute
(NHLBI). Details of mobilization, CD34 enrichment, transduction, and
transplantation of the animals included in this study were previously
reported in detail.25 The 3 macaques were 3 to 5 years of age (young adult)
at the time of transplantation in 2003.
Flow cytometric quantitation of GFP expression in various
hematopoietic cell subsets
Rhesus macaque peripheral blood (PB) and bone marrow (BM) cells were
incubated for 30 minutes at 4°C with PE-conjugated monoclonal antihuman
monoclonal antibodies, all cross-reactive to rhesus macaque antigens,
including CD3 (clone SP34), CD4 (clone M-T477), CD8 (clone RPA-T8),
CD11b (clone ICRF44), CD14 (clone M5E2), CD16 (clone 3G8), CD20
(clone 2H7), and CD34 (clone 563; all BD Biosciences PharMingen, San
Jose, CA). A BD LSR II analyzer (Becton Dickinson, San Jose, CA) was
used for analysis and 50 000 to 150 000 propidium-iodide excluding cells
were acquired for each sample. The percentage of GFP cells in hematopoi-
etic subsets as defined immunophenotypically by specific monoclonal
antibodies was measured.
qPCR quantitation of vector copy number in the genome of
various populations of hematopoietic cells
Genomic DNA from PB and BM nucleated cells, PB granulocytes, and
mononuclear cells purified by density gradient centrifugation over lympho-
cyte separation medium, or from subsets of PB cells separated by
multiparameter flow cytometric sorting, was extracted using Gentra Pure-
gene Cell Kit (QIAGEN, Valencia, CA) and then subjected to quantitative
polymerase chain reaction (qPCR) to estimate VCN. The sequences of the
primer/probe set for detection of the integrated SIV vector were as follows:
forward primer, 5-TACGGCTGAGTGAAGGCAGTAAG-3; reverse
primer, 5-CTCCTCACGCCGTCTGGTA-3; and the probe, 5-6-FAM-
AGGAACCAACCACGACGGAGTGCTC-TAMRA-3 (Applied Biosys-
tems, Foster City, CA). TaqMan ribosomal RNA control reagents (Applied
Biosystems) were used to normalize the amount of DNA analyzed. A
standard curve was established by analyzing duplicate aliquots of K562
DNA containing a single copy of the SIV vector genome serially diluted
with nontransduced K562 DNA. The qPCR was performed using the ABI
PRISM 7700 Sequence Detector (Applied Biosystems). For standards,
serial dilutions of DNA were prepared by mixing K562 DNA having a
single copy of the vector genome with nontransduced K562 DNA to yield
mixtures containing 1, 0.5, 0.25, 0.1, 0.01, and 0.001 vector copies. The
final VCN of each sample was adjusted by dividing the copy number by 1.5.
A coefficient of 1.5 was used because the K562 cell line used was
approximately triploid on average.
Southern blot analysis
The status and quantity of the vector genome was also evaluated in PB
and BM genomic DNA using Southern blot analysis. Serial control
dilutions were prepared by mixing K562 DNA having a single copy of
the vector genome with nontransduced K562 DNA in the proportions
indicated. Genome equivalent amounts of the standards and test PB and
BM genomic DNA were digested with BglII (New England Biolabs,
Ipswich, MA), which cuts twice in the vector genome, or with EcoR1,
which cuts once within the vector genome. The DNA fragments were
transferred to a charged nylon membrane and hybridized with a
radiolabeled GFP probe generated by digesting the SIV vector plasmid
with EcoRI and NotI, producing a 772-bp fragment containing
GFP sequences.
Identification and analysis of vector insertion sites
Linear amplification mediated (LAM)–PCR analysis was performed on
DNA extracted from granulocytes, T cells (CD3), and B cells (CD20), as
described.16 Sequencing was carried out via standard shotgun cloning as
described, or via 454 direct micropicoliter sequencing.29 For linear amplifi-
cation of the 5-SIV-LTR–genomic junction sites, 100 ng DNA was
amplified in 6 individual reactions or 600 ng DNA was used in a single
reaction. For the second (nested) exponential PCR, when 6 individual PCR
reactions were used in the linear amplification they were pooled and PCR
was performed using LAM-PCR primers adapted for 454 sequencing by
addition of a 19-bp sequence (sequencing primer) at the 5-end of both
forward and reverse nested primers. The reverse nested primer was
additionally modified by addition of a 4-bp bar code to allow identification
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of products from each individual time point, cell source, and animal. The
SIV-LTR–specific and linker cassette–specific primers for standard and
454 approaches are listed in Table S1, available on the Blood website; see
the Supplemental Materials link at the top of the online article. Amplicons
of junctions between genomic regions and 5-LTRs were purified from
agarose gels stained with crystal violet and directly sequenced using the
454 sequencing procedure (Genome Sequencer 20 System; University of
Florida, Gainesville, FL).
A sequence was considered a valid integration site if it was flanked
by both the expected SIV-LTR and the linker cassette sequences. We first
aligned each sequence to a locally maintained copy of the Rhesus
Macaque Genome Database (assembly MMUL 1.0, February 2006)30,31
using BLASTN.32 We filtered BLASTN results using 2 cutoff levels:
(1) at 95% identity over 95% of the length, and (2) at 90% identity over
90% of the length. Sequences mapping uniquely using both cutoffs were
kept as integrations. Sequences with ambiguous hits were mapped
manually using BLAT via the UCSC gateway (http://genome.ucsc.
edu)33 or megaBLAST.34 For gene annotation, Ensembl genebuild
August 2007 (http://www.ensembl.org) database version 45.10e compris-
ing 38 185 predicted gene transcripts was used.35
To generate control valid “random” datasets for comparisons, for
each experimentally determined integration site we generated in silico
LTR genomic integration coordinates using the following procedures:
(1) using a random number generator, select an AATT site at random
from the rhesus macaque genome; (2) select at random whether to use
sequence upstream or downstream of this site (each with probability
0.5); (3) extract a segment of genomic sequence that has the same length
as the sequence between the experimental LTR and AATT cloned
sequence; (4) compare this segment to the macaque genome by BLASTN;
(5a) if the sequence has a unique hit, keep the coordinate of the in silico
LTR, or (5b) if the segment does not have a unique BLAST hit, discard
that genomic sequence and begin again at step 1. Each control dataset
contains one in silico LTR coordinate for each experimentally identified
valid integration. For each group of integrations, we generated
10 000 control datasets. These control datasets were subjected to the
same analyses as the experimental datasets, and the results were used to
generate empiric P values. We generated a total of 5 groups of control
genomic coordinates, 1 for the 6- to 12-month integration dataset, 1 for
the 35- to 47-month dataset, 1 for the combined dataset including all
indentified SIV insertions, and 1 each for our Moloney murine leukemia
virus (MLV) and avian sarcoma leukosis virus (ASLV) datasets (these
have been previously described36).
Following the methods first proposed by Schwarzwaelder et al19 and
Suzuki et al,37 and modified more recently for analysis of genomic
insertions in polyclonal populations of cells, we defined a second-order
CIS as 2 or more integration sites within a window of 30 kb, a
third-order CIS as 3 or more integrations within 50 kb, and a fourth-
order CIS as 4 or more integrations within 100 kb. To find second-order
CISs, we placed the left edge of a 30-kb window on the first integration
site of a chromosome. If at least one additional integration site fell
within this window, we considered this window to contain one
second-order CIS. We then moved the left edge of the window to the
second integration site on a chromosome, and looked for a total of 2 or
more integration sites falling within this window. By this algorithm, if
3 integration sites A, B, and C fall within a 20-kb window, we would
count 2 second-order CISs, one containing sites A, B, and C, and the
second containing sites B and C. We used a similar method to find the
third- and fourth-order CISs, although we changed the window size
to 50 or 100 kb, and required at least 3 or at least 4 integration sites
to fall within that window. We applied this method of counting CISs
both to the experimental data and to the randomly selected in silico
integration sites.
Statistical significance was determined by 2 test, empiric t test, and
Fisher exact test as appropriate. P values less than .01 were considered
statistically significant. Bootstrapping methodology was also used to
analyze CIS and detailed in Table S2.
Results
Long-term, stable vector marking and transgene expression in
the hematopoietic progeny of transplanted, SIV
vector–transduced rhesus HSCs
The percentages of GFP-expressing cells of multiple hematopoietic
lineages in PB and BM were followed over time using multiparam-
eter flow cytometric analysis. Figure 1 shows serial quantitation of
the frequency of GFP granulocytes and lymphocytes in all
3 animals, out to more than 4 years after transplantation.
One monkey (CJ5B) showed stable GFP levels of greater than
10% and the other 2 animals (RQ2617 and RQ3556) had levels of
3% to 4%. Levels of GFP cells were similar in both myeloid and
lymphoid cells in each animal. Following an initial decrease in
level of GFP cells from peak values primarily 1 to 6 months after
transplantation, there was no further consistent decrement in the
frequency of transgene-expressing cells over time.
More detailed analysis of GFP expression in PB and BM T cells
and T-cell subsets, B cells, myeloid lineages, platelets, and red cells
was performed on samples at 44 to 47 months for all 3 animals
(Figure 2). Frequencies of GFP cells in the various lymphoid and
myeloid cell fractions were similar to overall levels, whereas the
frequencies of GFP red cells and platelets were lower, presumably
due to the short half-life of the GFP protein in these enucleate
cells.38 However, levels of GFP red cells and platelets were very
stable over the 4-year time frame (data not shown).
We compared the frequency of transgene-expressing cells as
detected by flow cytometry to the average vector copy number
(VCN) as assessed molecularly, both via real-time quantitative
PCR (qPCR) and Southern blot analysis. The DNA VCN ranged
from 1.3- to 3.7-fold higher than predicted from the GFP expres-
sion analysis (Figures 3,4). These results suggested the possibility
of some degree of vector silencing. To address this issue, we
evaluated the average VCN by qPCR in sorted GFP and GFP
granulocytes and lymphocytes in animals CJ5B and RQ3556. The
VCN in the sorted GFP cells was extremely low (0.01-0.07
copies), consistent with minimal transgene silencing and suggest-
ing that cells susceptible to transduction often integrated more than
a single vector copy (Figure 5). This interpretation was confirmed
by the average VCN we observed in the sorted, GFP populations.
We found that the average VCN ranged from around 1 to as high as
3 in the various sorted, GFP granulocyte and lymphocyte
populations. The average VCN data from the GFP sorted cell
populations was consistent with the quantitative differences we
observed between GFP expression and the overall VCN of PB
leukocytes (Figure 3). We also confirmed the lack of silencing by
analyzing clonogenic BM progenitors from animal CJ5B 47 months
after transplantation. We found that 2 of 20 colony-forming units
(CFUs) were GFP by microscopy (consistent with the  10% PB
myeloid marking), and, furthermore, none of the GFP colonies
were positive for vector sequences by DNA PCR analysis.
Polyclonal hematopoiesis as reflected by vector integration
site analysis
Vector insertion sites were identified and analyzed from granulo-
cytes, because they reflect ongoing hematopoiesis, at 35 to
47 months after transplantation. The products of LAM-PCR were
separated on Spreadex gels, with numerous bands resolved,
suggesting sustained polyclonality (data not shown). Southern blot
analysis of PB and BM DNA using an enzyme that cuts once in the
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vector showed no discernible hybridizing bands, indicative of the
lack of a significant dominant clonal population within the PB or
BM (Figure 4A). In contrast, when an enzyme was used that cut at
each end of the integrated provirus, a hybridizing band of the
correct predicted size was present in each sample at an intensity
corresponding to the qPCR VCN (Figure 4B).
All putative insertion sites were then identified using standard
shotgun cloning and sequencing or high-throughput direct sequenc-
ing via the 454 sequencing technology.29 Resultant valid sequences
were mapped using the rhesus macaque genome assembly (MMUL
1.0, February 2006).30,31 In comparison with mapping the same
sequences using the human genome assembly, more insertions
could be unequivocally identified. Our original database of SIV
insertions, mapped against the human genome, from samples
collected during the first year after transplantation in the same
animals was reanalyzed and mapped using the rhesus genome.36 A
total of 519 independent valid SIV insertions with locations that
could be unequivocally mapped to the rhesus genome were
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Figure 1. Stable, long-term SIV lentiviral vector expression in
myeloid and lymphoid cells of animals that received a trans-
plant. The percentage of GFP granulocytes (A) and lympho-
cytes (B) at various time points after transplantation in the 3 rhesus
macaques CJ5B, RQ2617, and RQ3556.
Figure 2. Long-term vector expression in numerous hematopoietic cell
subsets in the PB and BM of animals that received a transplant. The
percentage of various GFP-expressing hematopoietic cell types as defined by
immunophenotyping of peripheral blood and BM in animal CJ5B 4 years after
transplantation.
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identified (Table S3). Valid insertions located within repetitive
elements constituted an additional 30%, but could not be further
analyzed. Two-hundred eighty-nine sites were identified in granulo-
cytes at 6 to 12 months after transplantation, and 267 in granulo-
cytes 35 to 47 months after transplantation. Thirty-seven insertions
were present in both the 6- to 12-month and the 35- to 47-month
datasets, indicating that individual SIV vector–transduced progeni-
tor or stem cells present in the first year after transplantation were
able to contribute to hematopoiesis for prolonged time periods.
There were no differences between the patterns of SIV vector
integration patterns in clones contributing to hematopoiesis at 6 to
12 months versus 35 to 47 months after transplantation. Table 1
shows the characteristics of the pooled set of 519 SIV insertions
compared with in silico random integrations. As expected, there
was a very significant preference for integration within genes, and
in highly gene-dense regions. CpG islands were not targeted. As we
observed during the first year after transplantation, vector integra-
tions were slightly increased, relative to the random integration set,
near TSS (Figure S1). However, this observation is likely due to
integrations concentrated overall in and near gene coding sequences.
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Figure 3. Vector copy number compared with percentage of GFP cells
in PB and BM of animals that received a transplant. Comparison of the
percentage of GFP PB and BM cells as assessed by flow cytometry ([^])
and VCN as determined by qPCR of genomic DNA. For vector copy number,
mean of triplicate samples shown with error bars.
LTR LTRMSCV EGFP
IIlgBIIlgB
~5 kb
probe
A B
NEG  CJ5B     2617NEG  CJ5B     2617
Figure 4. Southern blot analysis corroborates polyclonality and VCN as determined by qPCR. (A) DNA was cut with EcoR1, which cuts once within the vector as shown.
Mixtures of DNA from a K562 cell line containing a single copy of the SIV vector with DNA from untransduced K562 cells in the proportions shown provide an estimate of the
sensitivity of the blot to detect clonal bands. (B) Estimation of vector copy number in PB and BM cells of animals CJ5B and RQ2617 by Southern blot analysis. DNA was cut with
BglII, which cuts twice in the vector genome as indicated, liberating a near full-length proviral genome that was detected by the indicated probe. Mixtures of DNA from a K562
cell line containing a single copy of the SIV vector with DNA from untransduced K562 cells in the proportions shown provide an estimate of the VCN in the rhesus samples
shown.
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We analyzed whether there was any significant clustering of
insertions at nonrandom sites in the genome, using the definitions
of common integration sites (CISs) proposed by Suzuki et al37
Figure 6 compares the number of CISs in the random datasets to
those in our actual dataset of 519 sites. The numbers of second-
order (2 sites within 30 kb), third-order (3 sites within 50 kb), and
fourth- or greater order (4 or more sites within 100 kb) CISs were
significantly more frequent in our SIV dataset than in our random
datasets (P  .001 for each order CIS). We also used a bootstrap-
ping methodology for comparing the experimental SIV dataset to
the 10 000 random computer-generated datasets, and as shown in
Table S2, these differences for each order CIS were also highly
significant.
We previously reported very marked clustering of MLV inser-
tions in or near the MDS1/EVI1 proto-oncogene locus (14 of a total
of 702 insertions) in the same rhesus model.39 We did not find any
insertions of SIV within or near ( 500 kb) from the MDS1/EVI1
locus, either early or late after transplantation, or in or near the
closely homologous PRDM16 locus (0/519; P 	 .001, Fisher exact
test). There was significant clustering in and around several genes,
although none have known proto-oncogenic properties (Table S3).
There were 5 independent insertions in the PACS1 (phosphofurin
acidic cluster sorting protein 1) gene locus. Three insertions were
identified at 6 to 12 months, one persisted at 35 to 47 months, and
an additional 2 were identified at the later time points. There were
4 insertions in the EYA3 locus, a member of the family of eyeless
proteins linked to a Drosphilia phenotype and having phosphatase
activity, but no known oncogenic or growth control function. There
were 4 independent insertions located within 4 kb of each other on
chromosome 14. This cluster was not within a gene, but is 2.2-kb
downstream from the alignment of a full-length human EST,
AK057104. The predicted gene product has no homology to known
proteins. There were also clusters of 4 insertions within 100 kb in
2 other regions of chromosome 14 and one region of chromosome
16. Proximity of all insertions to genes is given in Table S3.
We also analyzed the SIV integrants (Table 2) compared with in
silico–generated insertions regarding proximity to the entire class
of known oncogenes, as defined by the Sanger Cancer Gene Census
(http://www.sanger.ac.uk/genetics/CGP/Census).40 Despite normal-
ization for proximity to genes, there was a small but significant
increase in SIV vector integrations within or near oncogenes
(5.3%) compared with the random control set of integrations
(2.8%). This relative increase for the SIV vector was similar to that
observed for MLV vectors, and in contrast to an ASLV vector
(Table 2). This may reflect the propensity for SIV and MLV to
integrate in or near genes that are highly expressed,18,41 which
include many proto-oncogenes in HSCs.
Development of solid tumors in CJ5B and RQ3356
At 51 months after transplantation, CJ5B developed a large,
unresectable left tibial mass, necessitating euthanasia. Pathologic
evaluation showed osteosarcoma. The tumor cells did not express
GFP as judged by flow cytometry, and tumor DNA had an average
VCN of less than 0.006, likely due to low-level leukocyte
infiltration into the sample and not due to vector integration in
tumor cells. At 53 months after transplantation, animal RQ3356
was found to have a large posterior tongue squamous cell
carcinoma requiring euthanasia. These tumor cells were also GFP
negative by flow cytometry and DNA extracted from the tumor had
a mean copy number of less than 0.001, consistent with the tumor
lacking integrated vector. At autopsy, the cellularity and morphol-
ogy of the bone marrow were normal in both animals and they had
normal peripheral blood counts throughout the 4-year follow-up
period.
Discussion
The impetus for the development of lentiviral vectors more than a
decade ago was the inefficiency of transduction of quiescent cells
using standard -retroviral vectors based on Moloney murine
leukemia virus (MLV). HIV-based lentiviral vectors were demon-
strated to transduce nondividing cells such as neurons, due to
stability of the preintegration complex and ability to cross an intact
nuclear membrane and integrate into the host cell genome.22,42 HIV
vectors were also shown to transduce primitive human hematopoi-
etic cells more efficiently than -retroviral vectors, with minimal in
vitro culture and cytokine stimulation.43 However, the development
and use of lentiviral vectors for clinical applications was slowed, in
part, by inefficient vector production systems. Furthermore, the
apparent resounding success of -retroviral vectors in clinical trials
for immunodeficiency disorders may have hampered translational
development of lentiviral vectors.1,44
Table 1. Summary of SIV insertion site characteristics versus random in silico–generated integration datasets
All SIV, n 519, no. (%) Matching randoms, % P vs randoms
Sites within a gene 392 (75.5) 32.9 < .001
Sites within a CpG island or within a 1-kb
window of CpG island 1 (0.2) 1.0 .040
Distribution of sites relative to gene density
within 1-Mb window
0-10 genes 33.3 79.4 < .001
11-20 genes 29.5 15.5 < .001
More than 21 genes 37.2 5.1 < .001
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Figure 5. qPCR for VCN in GFP and GFP cell populations demonstrates the
lack of vector silencing. Vector copy number in the GFP (_) and GFP (f) sorted
granulocytes and lymphocytes of animals CJ5B and RQ3556. For vector copy
number, mean of triplicate samples shown with error bars.
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Initial results using HIV-based lentiviral vectors to transduce
HSCs in relevant large-animal models were disappointing. Levels
of stable, long-term gene transfer were lower than that of MLV
vectors, generally less than 1% long-term in baboons and rhesus
macaques.45-48 These poor results, in contrast to those achieved
with primitive human hematopoietic cells in xenograft models,
were later explained by the specific resistance of Old World
Monkey cells (including rhesus) to HIV infection or HIV vector
transduction.49 This led us to develop a replication-defective,
optimized SIV vector, specifically for transduction of nonhuman
primate HSCs. This vector has a self-inactivating, third-generation
design, with an internal MSCV LTR enhancer/promoter driving
expression of the GFP transgene. SIV vectors also transduce human
cells efficiently, and some of the safety and regulatory issues
associated with HIV vectors, such as seroconversion of patients,
might be avoided with SIV vectors.50
Before advancing into clinical trials targeting HSCs with SIV or
HIV vectors, prolonged follow-up data regarding persistence of
vector-containing cells, stability of expression, and safety are
crucial. The genotoxic events in trials using MLV vectors did not
become apparent until 3 years after transplantation. The current
study is the first to address these issues for lentiviral vectors in a
large-animal model. Previous nonhuman primate studies using
lentiviral vectors have reported results for only 6 to 12 months after
transplantation, and murine xenograft human progenitor studies
generally last only 3 to 4 months.25,45 Silencing of transgenes
carried by vectors can occur completely and abruptly shortly after
target cell infection, as shown most strikingly in embryonic
carcinoma and embryonic stem cells. Diminished expression in the
form of position effect variegation, due to asymmetric expression
in daughter cells, can also occur. In addition, loss of expression can
occur gradually over time despite initial high-level expression from
a provirus in a process termed extinction.51
Our current results indicate extended, stable levels of SIV
vector–transduced cells ranging from 3% to 13% in myeloid and
lymphoid lineages, after an initial decrease in marking levels
primarily between 3 and 6 months after transplantation, with no
further consistent diminution of marking levels or transgene
expression for up to 4 years after transplantation. The early
decrease was seen in our prior MLV studies as well, and likely
reflects more efficient transduction of short-term HSCs (ST-HSCs)
compared with true long-term (LT)–HSCs. LT-HSCs begin to
contribute 4 to 6 months after transplantation, as shown in our prior
studies where clones that stably contributed for years first appeared
6 months after transplantation.52 A detailed analysis showed no
evidence for significant levels of vector silencing, with vector copy
numbers in sorted GFP granulocytes and lymphocytes less than
0.1. Instead of vector silencing, the disparity between molecular
vector copy number and flow cytometric quantitation of GFP-
expressing cells was accounted for by an average VCN of greater
than 1 integrant per GFP cell. Within a heterogeneous population
of CD34 target cells, those cells that are susceptible to transduc-
tion may take up and integrate more than a single vector copy,
compared with other cells that may be resistant. Even in cell lines, a
30% initial transduction efficiency at the end of transduction,
similar to that achieved in this study, has been shown to result in a
significant number of clones with greater than one insert per cell.53
There are significant differences in integration patterns between
MLV and HIV or SIV vectors: MLV vectors have a moderate
propensity to integrate within gene coding regions, but a more
striking preference for areas surrounding transcription start sites,
compared with HIV/SIV vectors, with a higher preference for gene
coding regions but no marked preference for inserting near
transcription start sites.15,16,54 Both classes of vectors are more
likely to integrate in or near actively transcribed genes. Not
surprisingly, long-term follow-up of the animals studied in detail in
our current study documents a similar integration pattern for the
SIV lentiviral vector into long-term repopulating cells, compared
with the pattern we observed in these animals based on shorter
follow-up.
Long-term follow-up of our nonhuman primates revealed
important differences between MLV and SIV. In SIV animals, we
found no overrepresentation or, indeed, any examples of repopulat-
ing clones harboring SIV vector insertions into or near the
MDS1/EVI1, LMO2, or BCL2A1 loci. This is in marked contrast to
our results in the same rhesus model using MLV -retroviral
vectors, where we found 2% of all insertions located at MDS1/
EVI1.39 An even more striking frequency of insertions in this locus
was observed in the human CGD trial using MLV vectors, with
eventual clonal dominance of single abnormal clones, loss of
transgene expression, and disordered hematopoiesis.4,39 The lack of
MDS1/EVI1 as an overrepresented integration sites does not
guarantee lack of genotoxic risk, because other factors not yet
understood may impact on the integration pattern and other
proto-oncogenic loci may instead be an issue with lentiviral
vectors, however these findings are encouraging.
SIV integration sites were significantly more clustered com-
pared with our random datasets, with greater numbers of CISs of
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Figure 6. Comparison of the number of CISs found in the SIV
rhesus insertion dataset long term compared with 10 000
random datasets. CISs of second, third, and fourth order were
identified in the SIV dataset and in the 10 000 random datasets
as defined and described in “Identification and analysis of vector
insertion sites.” The x-axis gives the number of CISs and the
y-axis, the number of datasets containing that number of CISs.
The arrows show the number of each order CIS found in the
experimental SIV datasets. P values were all less than .001
comparing second-, third-, and fourth-order CISs in the SIV
experimental dataset to the 10 000 random datasets.
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second-, third-, and higher orders. We also detected small, but
higher than expected frequencies of integrants for both MLV- and
SIV-based vectors into or near proto-oncogenes, most likely based
on the high-level expression of many of these growth-promoting
genes in primitive hematopoietic cells.18 These and other sites of
clustering may be due to specific physical characteristics of
chromatin at these sites that favor integration of lentiviruses, due to
high gene density, histone configuration, or other factors. Despite
the increased rate of integration of both vectors into or near
proto-oncogenes, no SIV vector–containing clone has clearly
expanded or become dominant in vivo and no individual proto-
oncogene was overrepresented as a common integration site, which
is reassuring for advancing clinical development of SIV and HIV
vectors. In a tumor-prone murine bone marrow transplantation
model, a much higher incidence of insertional leukemias was found
with MLV compared with HIV vectors.55
Five independent insertions in the PACS1 locus were identified.
The PACS1 gene product has no known impact on cell survival or
proliferation and is not included on any cancer-related gene
inventories. It is a protein involved in controlling the localization of
proteins in subcellular organelles.56 Of note, it has been found to
participate in the trafficking of viral envelope glycoproteins during
production viral infection and release, interacting with acidic
residues on the RD114 env protein to sequester it away from SIV
gag, decreasing release of RD114-pseudotyped SIV particles.57
Because PACS1 is highly expressed in primitive human hematopoi-
etic stem and progenitor cells, we speculate that the open pattern of
chromatin and particular chromatin-binding patterns present at this
locus in stem cells might be responsible for attracting integration
complexes.58 The other loci with significant overrepresentation,
including EYA3 and regions on chromosomes 4, 14, and 16, have
no known impact on cellular properties likely to impact on
oncogenesis or genotoxicity, but further investigation will be
important if these loci are also represented in independent SIV or
HIV insertion datasets.
All third-generation lentiviral vectors, including all those used
in the insertion site analyses in this study, have a “self-inactivating”
(SIN) design. Enhancer regions have been deleted from the 3 LTR,
and the integration process results in removal of the enhancer from
the integrated 5 LTR as well. Therefore, the increased genotoxicity
of MLV vectors, compared with HIV/SIV, resulting from activation
of adjacent oncogenes is likely due to potent enhancer elements
that reside in the LTRs, as suggested by others.26 The results of our
current study argue that other factors, such as vector system–
specific integration site selection, may also play an important role,
because our vector contained an internal MLV LTR promoter-
enhancer, optimized for very high expression in primitive hemato-
poietic cells, driving the GFP transgene.60 Despite the presence of
one copy of this strong LTR enhancer in our SIV vector, there was
no evidence for clonal dominance via activation of MDS1/EVI1 or
LMO2, or progression toward abnormal hematopoiesis or leuke-
mia. This result suggests that a strong internal enhancer/promoter
in an integrated lentiviral vector may have less potent effects on
neighboring genes than 2 intact LTRs on either end of an integrated
-retroviral vector. Modlich et al recently reported that SIN MLV
vectors with an internal LTR promoter had less potent but still
active transforming activity than intact MLV vectors.60
The occurrence of malignant tumors in 2 of the 3 animals is
concerning, however, we could find no evidence of vector se-
quences or transgene expression in either tumor. There is limited
long-term follow-up data regarding the incidence of tumors in
cohorts of aging rhesus macaques, and no relevant information onTa
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macaques exposed to irradiation, in particular high-dose total body
irradiation. The 2 animals were 7 and 8 years of age when they
developed the tumors. A study from 1973 reported on the incidence
of spontaneous neoplasia in 1065 adult monkeys from 32 species
and found tumors in only 2.8%, however these were animals
entered in multiple different studies and most were older animals.61
In a much smaller aging study, 164 necropsies were performed on
macaques 15 years of age or older that died spontaneously or were
euthanized for medical problems.62 None had been irradiated. In
30%, tumors were discovered, including one oral squamous
carcinoma and one osteosarcoma. In other large-animal models and
in humans, both osteosarcomas and squamous cell carcinomas have
been linked to prior radiation exposure.63-65 One canine study
reported osteosarcomas developing in almost 10% of dogs fol-
lowed for 1.2 to 6.4 years after high-dose radiation therapy.66 So
although we remain concerned regarding the occurrence of these
tumors, the evidence so far strongly suggests they are linked to the
irradiation, not the SIV gene transfer vector. The development of
effective nonmyeloablative, nonmutagenic, and less toxic condition-
ing regimens, particularly for nonmalignant target diseases, is
crucial for any wide application of gene therapy targeting HSCs.
Continued follow-up of the surviving and additional animals that
received a transplant of SIV lentiviral vector–transduced cells will be
important. However, the results thus far, combined with evidence from
tumor-prone murine models, are encouraging regarding decreased
genotoxicity of SIN lentiviral vectors compared with MLV vectors for
transduction of primitive hematopoietic cells. We have achieved stable
long-term and high-level transgene expression, and further optimization
of transduction conditions, vector design, and conditioning regimens
may result in higher levels of circulating genetically modified cells. It
should be noted that it took almost 20 years to achieve therapeutic levels
of gene transfer to primitive hematopoietic cells after the initial
development of replication-incompetent -retroviral vectors. The levels
of genetic modification and stable expression we observed in this study
could be therapeutic for several clinical applications, such as chronic
granulomatous disease (CGD) and the hemoglobin disorders.67,68 Clini-
cal trials are already ongoing using HIV-based lentiviral vectors to
transduce target HSCs in patients with thalassemia and
adrenoleukodystrophy.
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